4.7 Review

Significance of Levocarnitine Treatment in Dialysis Patients

期刊

NUTRIENTS
卷 13, 期 4, 页码 -

出版社

MDPI
DOI: 10.3390/nu13041219

关键词

carnitine; carnitine deficiency; end-stage kidney disease; peritoneal dialysis; hemodialysis

向作者/读者索取更多资源

Carnitine is a naturally occurring amino acid derivative involved in the transport of long-chain fatty acids and energy production. In patients on dialysis, serum carnitine levels may decrease due to restricted dietary intake and deprivation of endogenous synthesis, leading to various clinical disorders. Levocarnitine administration may help replenish free carnitine and increase carnitine levels in muscle, potentially improving symptoms in dialysis patients.
Carnitine is a naturally occurring amino acid derivative that is involved in the transport of long-chain fatty acids to the mitochondrial matrix. There, these substrates undergo beta-oxidation, producing energy. The major sources of carnitine are dietary intake, although carnitine is also endogenously synthesized in the liver and kidney. However, in patients on dialysis, serum carnitine levels progressively fall due to restricted dietary intake and deprivation of endogenous synthesis in the kidney. Furthermore, serum-free carnitine is removed by hemodialysis treatment because the molecular weight of carnitine is small (161 Da) and its protein binding rates are very low. Therefore, the dialysis procedure is a major cause of carnitine deficiency in patients undergoing hemodialysis. This deficiency may contribute to several clinical disorders in such patients. Symptoms of dialysis-related carnitine deficiency include erythropoiesis-stimulating agent-resistant anemia, myopathy, muscle weakness, and intradialytic muscle cramps and hypotension. However, levocarnitine administration might replenish the free carnitine and help to increase carnitine levels in muscle. This article reviews the previous research into levocarnitine therapy in patients on maintenance dialysis for the treatment of renal anemia, cardiac dysfunction, dyslipidemia, and muscle and dialytic symptoms, and it examines the efficacy of the therapeutic approach and related issues.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据